北陸藥業(300016.SZ):獲得西甲硅油乳劑的藥品註冊證書
格隆匯2月7日丨北陸藥業(300016.SZ)公佈,近日,北京北陸藥業股份有限公司收到國家藥品監督管理局核准簽發的西甲硅油乳劑《藥品註冊證書》。
西甲硅油乳劑是由德國柏林化學股份有限公司研製開發的口服納米乳劑,是臨牀常用的祛泡劑,適應症為:(1)用於治療由胃腸道中聚集了過多氣體而引起的不適症狀:如腹脹等,術後也可使用;(2)可作為腹部影像學檢查的輔助用藥(例如:X-線、超聲、胃鏡檢查)以及作為雙重對比顯示的造影劑懸液的添加劑。西甲硅油乳劑安全性高,受眾人羣廣(嬰兒至成人),孕婦及哺乳期婦女均可服用。
米內網數據顯示,2023年國內西甲硅油乳劑銷售額超過3.75億元,同比增長21.43%;2024年上半年,國內西甲硅油乳劑銷售額超過2.21億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.